The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data<sup/>.
第一作者:
Sarah C,Rutherford
第一单位:
a Department of Medicine, Division of Hematology and Oncology , Meyer Cancer Center, Weill Cornell Medicine and New York-Presbyterian Hospital , New York , NY , USA.
作者:
主题词
抗病毒药(Antiviral Agents);真核细胞起始因子4E(Eukaryotic Initiation Factor-4E);人类(Humans);淋巴瘤(Lymphoma);缓解诱导(Remission Induction);呼吸道合胞体病毒感染(Respiratory Syncytial Virus Infections);呼吸道合胞病毒(Respiratory Syncytial Viruses);回顾性研究(Retrospective Studies);利巴韦林(Ribavirin)
DOI
10.1080/10428194.2017.1323270
PMID
28573908
发布时间
2019-01-16
- 浏览0

Leukemia & lymphoma
256-258页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文